37.93
price down icon3.93%   -1.55
pre-market  Pre-market:  39.85   1.92   +5.06%
loading
Cytokinetics Inc stock is traded at $37.93, with a volume of 1.88M. It is down -3.93% in the last 24 hours and down -16.51% over the past month. Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$39.48
Open:
$38.9
24h Volume:
1.88M
Relative Volume:
1.00
Market Cap:
$4.55B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-7.211
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-4.72%
1M Performance:
-16.51%
6M Performance:
-29.51%
1Y Performance:
-43.85%
1-Day Range:
Value
$37.45
$39.28
1-Week Range:
Value
$37.45
$40.22
52-Week Range:
Value
$32.74
$68.76

Cytokinetics Inc Stock (CYTK) Company Profile

Name
Name
Cytokinetics Inc
Name
Phone
(650) 624-3000
Name
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
498
Name
Twitter
@Cytokinetics
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
CYTK's Discussions on Twitter

Compare CYTK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CYTK
Cytokinetics Inc
37.93 4.55B 18.47M -589.53M -399.80M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-07-25 Initiated Citigroup Buy
Jan-22-25 Initiated Stifel Buy
Nov-08-24 Initiated RBC Capital Mkts Outperform
Aug-13-24 Downgrade Goldman Buy → Neutral
Jan-24-24 Downgrade UBS Buy → Neutral
Jan-05-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-23 Initiated Goldman Buy
Nov-07-23 Initiated B. Riley Securities Buy
Aug-15-23 Initiated SVB Securities Outperform
Feb-17-23 Initiated BofA Securities Neutral
Dec-23-22 Reiterated Needham Buy
Dec-20-22 Initiated Truist Buy
Oct-11-22 Initiated UBS Buy
Jan-28-22 Initiated Goldman Buy
Dec-22-21 Initiated Oppenheimer Outperform
Dec-10-21 Initiated JP Morgan Overweight
Oct-07-21 Initiated Jefferies Buy
Mar-12-21 Initiated Wolfe Research Outperform
Feb-18-21 Initiated Barclays Overweight
Jan-20-21 Reiterated H.C. Wainwright Buy
Oct-29-20 Initiated Goldman Neutral
Jul-10-20 Initiated Raymond James Strong Buy
May-05-20 Initiated Mizuho Buy
Apr-09-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Sep-10-18 Resumed Morgan Stanley Equal-Weight
Nov-22-17 Reiterated Morgan Stanley Overweight
Nov-22-17 Downgrade Needham Strong Buy → Buy
Nov-21-17 Reiterated H.C. Wainwright Buy
Jul-31-17 Initiated Morgan Stanley Overweight
Mar-08-17 Initiated Rodman & Renshaw Buy
Feb-06-17 Upgrade Needham Buy → Strong Buy
Dec-16-16 Initiated Cantor Fitzgerald Overweight
Jul-28-16 Reiterated Needham Buy
Nov-10-15 Reiterated FBR Capital Outperform
Nov-09-15 Reiterated ROTH Capital Buy
Jul-24-15 Reiterated MLV & Co Buy
Dec-31-14 Reiterated ROTH Capital Buy
Nov-04-14 Upgrade MLV & Co Hold → Buy
Apr-28-14 Reiterated Needham Buy
View All

Cytokinetics Inc Stock (CYTK) Latest News

pulisher
Apr 21, 2025

Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach - Benzinga

Apr 21, 2025
pulisher
Apr 21, 2025

Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India

Apr 21, 2025
pulisher
Apr 18, 2025

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com

Apr 18, 2025
pulisher
Apr 17, 2025

Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo

Apr 17, 2025
pulisher
Apr 17, 2025

10 Best High Short Interest Stocks to Buy Now - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 17, 2025
pulisher
Apr 17, 2025

Cytokinetics Strategic Talent Push: 13 New Hires Receive Major Equity Package Worth $3.9M - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 16, 2025

Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance

Apr 15, 2025
pulisher
Apr 14, 2025

Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 11, 2025

Cytokinetics, IncorporatedCommon Stock (NQ: CYTK - FinancialContent

Apr 11, 2025
pulisher
Apr 10, 2025

Cytokinetics CEO Robert Blum sells $183,850 in stock By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Cytokinetics CEO Robert Blum sells $183,850 in stock - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

JMP reiterates Cytokinetics stock with $78 target on HCM trial optimism - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics - Endpoints News

Apr 10, 2025
pulisher
Apr 10, 2025

Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes - TipRanks

Apr 10, 2025
pulisher
Apr 09, 2025

Cytokinetics stock plunges to 52-week low of $33.67 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Cytokinetics’ CK-4021586 improves cardiac function in HFpEF - BioWorld MedTech

Apr 09, 2025
pulisher
Apr 09, 2025

Cytokinetics (NASDAQ:CYTK) Given "Buy" Rating at HC Wainwright - MarketBeat

Apr 09, 2025
pulisher
Apr 08, 2025

Cytokinetics EVP sells $72,360 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Cytokinetics EVP sells $72,360 in stock - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - Investing.com

Apr 08, 2025
pulisher
Apr 07, 2025

Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Cytokinetics CCO Andrew Callos sells $103k in stock By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Cytokinetics CCO Andrew Callos sells $103k in stock - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health - Investing.com

Apr 07, 2025
pulisher
Apr 05, 2025

Cytokinetics director Robert Harrington sells shares worth $17,743 By Investing.com - Investing.com South Africa

Apr 05, 2025
pulisher
Apr 05, 2025

Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com Australia

Apr 05, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 04, 2025

Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 03, 2025

Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Cytokinetics stock holds $78 target from JMP amid trial results - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus

Apr 03, 2025
pulisher
Apr 02, 2025

Why These Two Biotech Stocks Just Diverged - Investor's Business Daily

Apr 02, 2025
pulisher
Apr 02, 2025

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia

Apr 02, 2025
pulisher
Apr 02, 2025

Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK

Apr 02, 2025
pulisher
Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha

Apr 02, 2025
pulisher
Apr 01, 2025

Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals

Apr 01, 2025
pulisher
Mar 31, 2025

Cytokinetics CEO Makes Major Stock Move! - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals

Mar 31, 2025

Cytokinetics Inc Stock (CYTK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):